Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy

Nat Commun. 2022 Oct 3;13(1):5820. doi: 10.1038/s41467-022-33331-8.

Abstract

The function of interleukin-22 (IL-22) in intestinal barrier homeostasis remains controversial. Here, we map the transcriptional landscape regulated by IL-22 in human colonic epithelial organoids and evaluate the biological, functional and clinical significance of the IL-22 mediated pathways in ulcerative colitis (UC). We show that IL-22 regulated pro-inflammatory pathways are involved in microbial recognition, cancer and immune cell chemotaxis; most prominently those involving CXCR2+ neutrophils. IL-22-mediated transcriptional regulation of CXC-family neutrophil-active chemokine expression is highly conserved across species, is dependent on STAT3 signaling, and is functionally and pathologically important in the recruitment of CXCR2+ neutrophils into colonic tissue. In UC patients, the magnitude of enrichment of the IL-22 regulated transcripts in colonic biopsies correlates with colonic neutrophil infiltration and is enriched in non-responders to ustekinumab therapy. Our data provide further insights into the biology of IL-22 in human disease and highlight its function in the regulation of pathogenic immune pathways, including neutrophil chemotaxis. The transcriptional networks regulated by IL-22 are functionally and clinically important in UC, impacting patient trajectories and responsiveness to biological intervention.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chemokines, CXC / metabolism
  • Colitis, Ulcerative* / drug therapy
  • Colitis, Ulcerative* / genetics
  • Humans
  • Interleukin-22
  • Interleukin-8 / metabolism
  • Interleukins
  • Neutrophil Infiltration
  • Neutrophils / metabolism
  • Receptors, Interleukin-8B / metabolism
  • Ustekinumab / pharmacology
  • Ustekinumab / therapeutic use

Substances

  • Chemokines, CXC
  • Interleukin-8
  • Interleukins
  • Receptors, Interleukin-8B
  • Ustekinumab